A 26-week, Multicenter, Open-label, Fleible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants with Schizophrenia or ipolar I Disorder
This is a 26-week open-label study to evaluate the safety and effectiveness of the study drug in the treatment of pediatric participants with schizophrenia or bipolar I disorder.
(CSR 200939856165) The purpose of this study is to evaluate the long-term safety and tolerability of cariprazine in the treatment of pediatric participants with schizophrenia or bipolar I disorder.
Males and females ages 13 to 18 with schizophrenia or 10 to 18 years of age with bipolar I disorder may be eligible for the study.
Let us know how the study team can reach you.
If you do not hear back within 2 business days, reach out to the study team directly at the contact information above or email email@example.com and someone will assist you.